Pliant Therapeutics, Inc.
NASDAQ: PLRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bernard Coulie
- Employees
- 171
- Headquarters
- South San Francisco, United States
- IPO year
- 2020
- Market cap
- $70.0M
- Website
- https://pliantrx.com
Loading PLRX…
Loading profile data…Frequently asked questions about PLRX
What does Pliant Therapeutics, Inc. (PLRX) do?
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibit...
Where does PLRX trade?
Pliant Therapeutics, Inc. (PLRX) trades on the NASDAQ Global Select.
What sector is PLRX in?
Pliant Therapeutics, Inc. (PLRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pliant Therapeutics, Inc.?
Bernard Coulie is the chief executive officer of Pliant Therapeutics, Inc. (PLRX).
Where is Pliant Therapeutics, Inc. headquartered?
Pliant Therapeutics, Inc. is headquartered in United States.
Does PLRX pay a dividend?
Pliant Therapeutics, Inc. (PLRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PLRX go public?
Pliant Therapeutics, Inc. (PLRX) completed its initial public offering in 2020.